Browsing by Author "Sahin, E"
Now showing 1 - 10 of 10
Results Per Page
Sort Options
Item Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3Batir, MB; Sahin, E; Cam, FSProstate cancer is a common health problem among men worldwide and most of these prostate cancer cases are related to a dysfunctional mutant Tumor Protein p53 (TP53) gene. However, the CRISPR/Cas9 system can be used for repairing of a dysfunctional mutant TP53 gene in combination with donor single-stranded oligodeoxynucleotide (ssODN) via cells' own homology-directed repair (HDR) mechanism. In this study, we aimed to evaluate the CRISPR/Cas9 repairing efficiency on TP53 414delC (p.K139fs*31) null mutation, located in the TP53 gene, of human prostate cancer cell line PC-3 in combination with ssODNs. According to the next-generation sequencing results, TP53 414delC mutation was repaired with an efficiency of 19.95% and 26.0% at the TP53 414delC position with ssODN1 and ssODN2 accompanied by sgRNA2 guided CRISPR/Cas9, respectively. Besides, qPCR and immunofluorescence analysis showed that PC-3 cells, the TP53 414delC mutation of which were repaired, expressed wild type p53 again. Also, significantly increased number of apoptotic cells, driven by the repaired TP53 gene were detected compared to the control cells by flow cytometry analysis. As a result, sgRNA2 guided CRISPR/Cas9 system accompanied by ssODN was shown to effectively repair the TP53 414delC gene region and inhibit the cell proliferation of PC-3 cells. Therefore, the effects of the TP53 414delC mutation repairment in PC-3 cells will be investigated in the in vivo models for tumor clearance analysis in the near future.Item Determination of Satisfaction Levels of Faculty of Sport Sciences Education ServiceSahin, E; Göral, M; Demirel, M; Demirel, DH; Arslan, FThe aim of this study, was to determine the satisfaction levels related to different variables of their educational in stitutes of the students in Faculty Of Sport Science. In the study, student satisfaction scale (short form)' is used. The validity and reliability of this scale has been done in 2011 by BAYKAL and friends. The sample group of the study was totally 259 university students from different parts of Pamukkale University sports science and technology department. SPSS package program was used for the statistical analysis of the study data. Cronbach Alpha was determined fort his study as .94 and between .92-.93 for sub-dimensions. Kolmogorov-Smirnov test was applied normal distribution has been determined. For this reason, in addition to descriptive statistical methods such as, frequency (f), percentage (%), T test and one way ANOVA test was used to determine any differncies of age, class, and well-being. No significant differences were determined according to their level of well-being and class, but it has been determined 0.5 statistical significal different of age. As a result, the age variable is an important variable in determining the satisfaction level of students in educational services and educational services by the variable of age may be a significant difference was determined at the level of satisfaction.Item Oleuropein Has Modulatory Effects on Systemic Lipopolysaccharide-Induced Neuroinflammation in Male RatsSahin, S; Sahin, E; Esenülkü, G; Renda, G; Gürgen, SG; Alver, A; Abidin, I; Cansu, ABackground: Neuroin fl ammation induced by systemic in fl ammation is a risk factor for developing chronic neurologic disorders. Oleuropein (OLE) has antioxidant and anti-in fl ammatory properties; however, its effect on systemic in fl ammation-related neuroin fl ammation is unknown. Objectives: This study aimed to determine whether OLE protects against systemic lipopolysaccharide (LPS)-induced neuroin fl ammation in rats. Methods: Six-wk-old Wistar rats were randomly assigned to 1 of the following 5 groups: 1 ) control, 2 ) OLE-only, 3 ) LPS & thorn; vehicle, 4 ) OLE & thorn; LPS (O-LPS), and 5 ) a single-dose OLE & thorn; LPS (SO-LPS group). OLE 200 mg/kg or saline as a vehicle was administered via gavage for 7 d. On the seventh day, 2.5 mg/kg LPS was intraperitoneally administered. The rats were decapitated after 24 h of LPS treatment, and serum collection and tissue dissection were performed. The study assessed astrocyte and microglial activation using glial fi brillary acidic protein (GFAP) and CD11b immunohistochemistry, nod -like receptor protein -3, interleukin (IL)-1 beta , IL -17A, and IL -4 concentrations in prefrontal and hippocampal tissues via enzyme-linked immunosorbent assay, and total antioxidant/oxidant status (TAS/TOS) in serum and tissues via spectrophotometry. Results: In both the O-LPS and SO-LPS groups, LPS-related activation of microglia and astrocytes was suppressed in the cortex and hippocampus ( P < 0.001), excluding cortical astrocyte activation, which was suppressed only in the SO-LPS group ( P < 0.001). Hippocampal GFAP immunoreactivity and IL -17A concentrations in the dentate gyrus were higher in the OLE group than those in the control group, but LPS-related increases in these concentrations were suppressed in the O-LPS group. The O-LPS group had higher cortical TAS and IL -4 concentrations. Conclusions: OLE suppressed LPS-related astrocyte and microglial activation in the hippocampus and cortex. The OLE-induced increase in cortical IL -4 concentrations indicates the induction of an anti-in fl ammatory phenotype of microglia. OLE may also modulate astrocyte and IL -17A functions, which could explain its opposing effects on hippocampal GFAP immunoreactivity and IL -17A concentrations when administered with or without LPS.Item Artificial neural network investigation of injectability and percolation of highly filled β -Tricalcium phosphate suspensionsKulakoglu, S; Yalamaç, E; Sahin, EOver the past few decades, calcium phosphate cement has been used successfully for bone reconstruction applications. As percutaneous surgical methods have developed, there is an increased interest in calcium phosphate cement injection behavior. The aim of this study is to minimize percolation (liquid phase migration under pressure) and maximize injectability (ratio of the extruded part to whole) of highly filled beta-tri calcium phosphate (beta-TCP) suspensions by varying capillary flow process parameters with an artificial neural network (ANN) approach. The effects of hydroxyethyl cellulose (HEC) and polyethylene glycol (PEG-400) were also studied as binder additives for injectable beta-tri calcium phosphate pastes. Prepared suspensions were investigated by capillary and small amplitude oscillatory rheometry. The study predicted experimental input and output data by using Backpropagation Neural networks via the Levenberg-Marquardt algorithm. The ANN model was developed by feed-forward back propagation network and predict percolation (%) and injectability (%). A great agreement was observed between the predicted values by the ANN model and the experimental data for injectability (%) and percolation (regression coefficients) of 0.9984 and 0.9982 respectively. The results depict that ANNs can improve the accuracy of injectability and percolation results which can be used to optimize process and additive parameters for injectable bone cements and pastes. 2 wt% HEC was determined as the most effective factor to improve the rheological properties of highly filled beta-TCP pastes which could be injected as much as 99.21 % at a rate of 15 mm/min through dies with L/D ratio of 15. Their percolation value was calculated as 0.82 %. Lubricative effect of PEG-400 additive with 2 wt% HEC to reduce injection force was also demonstrated.Item Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)Karacin, C; Oksuzoglu, B; Demirci, A; Keskinkiliç, M; Baytemür, NK; Yilmaz, F; Selvi, O; Erdem, D; Avsar, E; Paksoy, N; Demir, N; Göksu, SS; Türker, S; Bayram, E; Çelebi, A; Yilmaz, H; Kuzu, ÖF; Kahraman, S; Gökmen, I; Sakin, A; Alkan, A; Nayir, E; Ugrakli, M; Acar, Ö; Ertürk, I; Demir, H; Aslan, F; Sönmez, Ö; Korkmaz, T; Celayir, ÖM; Karadag, I; Kayikçioglu, E; Sakalar, T; Öktem, IN; Eren, T; Erul, E; Mocan, EE; Kalkan, Z; Yildirim, N; Ergün, Y; Akagündüz, B; Karakaya, S; Kut, E; Teker, F; Demirel, BÇ; Karaboyun, K; Almuradova, E; Ünal, OÜ; Oyman, A; Isik, D; Okutur, K; Öztosun, B; Gülbagci, BB; Kalender, ME; Sahin, E; Seyyar, M; Özdemir, Ö; Selçukbiricik, F; Kanitez, M; Dede, I; Gümüs, M; Gökmen, E; Yaren, A; Menekse, S; Ebinç, S; Aksoy, S; Imamoglu, GI; Altinbas, M; Çetin, B; Uluç, BO; Er, Ö; Karadurmus, N; Erdogan, AP; Artaç, M; Tanriverdi, Ö; Çiçin, I; Sendur, MAN; Oktay, E; Bayoglu, IV; Paydas, S; Aydiner, A; Salim, DK; Geredeli, Ç; Yavuzsen, T; Dogan, M; Hacibekiroglu, IItem Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyKaracin, C; Oksuzoglu, B; Demirci, A; Keskinkiliç, M; Baytemür, NK; Yilmaz, F; Selvi, O; Erdem, D; Avsar, E; Paksoy, N; Demir, N; Göksu, SS; Türker, S; Bayram, E; Çelebi, A; Yilmaz, H; Kuzu, ÖF; Kahraman, S; Gökmen, I; Sakin, A; Alkan, A; Nayir, E; Ugrakli, M; Acar, Ö; Ertürk, I; Demir, H; Aslan, F; Sönmez, Ö; Korkmaz, T; Celayir, ÖM; Karadag, I; Kayikçioglu, E; Sakalar, T; Öktem, IN; Eren, T; Urul, E; Mocan, EE; Kalkan, Z; Yildirim, N; Ergün, Y; Akagündüz, B; Karakaya, S; Kut, E; Teker, F; Demirel, BÇ; Karaboyun, K; Almuradova, E; Ünal, OÜ; Oyman, A; Isik, D; Okutur, K; Öztosun, B; Gülbagci, BB; Kalender, ME; Sahin, E; Seyyar, M; Özdemir, Ö; Selçukbiricik, F; Kanitez, M; Dede, I; Gümüs, M; Gökmen, E; Yaren, A; Menekse, S; Ebinç, S; Aksoy, S; Imamoglu, GI; Altinbas, M; Çetin, B; Uluç, BO; Er, Ö; Karadurmus, N; Erdogan, AP; Artaç, M; Tanriverdi, Ö; Çiçin, I; Sendur, MAN; Oktay, E; Bayoglu, IV; Paydas, S; Aydiner, A; Salim, DK; Geredeli, Ç; Yavuzsen, T; Dogan, M; Hacibekiroglu, IBackground There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and >= 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.Item In vivo tissue response and durability of five novel synthetic polymers in a rabbit modelSahin, E; Cingi, C; Eskiizmir, G; Altintoprak, N; Calli, A; Calli, C; Yilgör, I; Yilgör, EAlloplastic materials are frequently used in facial plastic surgeries such as rhinoplasty and nasal reconstruction. Unfortunately, the ideal alloplastic material has not been found. This experimental study evaluates the tissue response and durability of five novel polymers developed as an alloplastic material. In this experimental study involving a tertiary university hospital, six subcuticular pockets were formed at the back of 10 rabbits for the implantation of each polymer and sham group. Each pocket was excised with its adjacent tissue after three months, and collected for histopathological examination. Semi-quantitative examination including neovascularisation, inflammation, fibrosis, abscess formation, multinucleated foreign body giant cells was performed, and integrity of polymer was evaluated. A statistical comparison was performed. No statically significant difference was detected in neovascularisation, inflammation, fibrosis, abscess formation and multinucleated foreign body giant cells when a paired comparison between sham and polymer II, II and IV groups was performed individually. Nevertheless, the degree of fibrosis was less than sham group in polymer I (p = .027) and V (p = .018), although the other variables were almost similar. The integrity of polymers II (9 intact, 1 fragmented) and IV (8 intact, 2 absent) was better than the other polymers. These novel synthetic polymers could be considered as good candidates for clinical applicability. All polymers provided satisfactory results in terms of tissue response; however, fibrovascular integration was higher in polymers II, II and IV. In addition, the durability of polymer II and IV was better than the others.Item Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaYildirim, HC; Bayram, E; Chalabiyev, E; Majidova, N; Avci, T; Güzel, HG; Kapar, C; Uzun, M; Perkin, P; Akgül, F; Yildirim, SS; Sali, S; Yildiz, A; Kazaz, SN; Hendem, E; Arcagok, M; Tufan, G; Yildirim, U; Akgul, OF; Arslan, C; Taban, H; Sahin, E; Caglayan, M; Esen, R; Öksüzoglu, B; Guven, DC; Kaplan, MA; Araz, M; Basaran, M; Cubukcu, E; Gokmen, E; Cicin, I; Algin, E; Semiz, HS; Tural, D; Ozturk, B; Erdogan, AP; Sari, M; Kara, O; Erman, MNon-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib. Pazopanib and sunitinib treatments show similar progression free survival, overall survival and objective response rate.IMDC risk group, liver metastasis, sarcomatoid component and de novo metastatic disease were determined as prognostic factorsItem Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG studyBeypinar, I; Demir, H; Yaslikaya, S; Köseci, T; Demir, B; Çolak, G; Agaoglu, AB; Sahbazlar, M; Sanci, PC; Cabuk, D; Isik, U; Sahin, E; Coskun, A; Caner, B; Aykut, T; Artac, M; Duygulu, ME; Sever, N; Öksüz, S; Turan, N; Aykan, MB; Tüzün, EK; Uysal, M; Ugurlu, I; Sakin, A; Acar, C; Özaskin, D; Sakalar, T; Keskinkilic, M; Yavuzsen, T; Köse, N; Ertürk, I; Yildirim, N; Balçik, OY; Alkan, A; Selvi, O; Ercin, E; Ünal, OU; Karaçin, CPurpose In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.Item Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART)Ecevit, MC; Özcan, M; Can, IH; Tatar, EC; Özer, S; Esen, E; Atan, D; Göde, S; Elsurer, C; Eryilmaz, A; Coskun, BU; Yazici, ZM; Dinç, ME; Ozdogan, F; Gunhan, K; Bilal, N; Korkut, AY; Kasapoglu, F; Türk, B; Server, EA; Çelebi, ÖÖ; Simsek, T; Kum, RO; Adali, MK; Eren, E; Aslier, NGY; Bayindir, T; Çetin, AC; Göker, AE; Güvenç, IA; Köseoglu, S; Özler, GS; Sahin, E; Yilmaz, AS; Güne, C; Yildirim, GA; Öca, B; Durmusoglu, M; Kantekin, Y; Özmen, S; Kubat, GO; Sanal, SK; Altuntas, EE; Selçuk, A; Yazici, H; Baklaci, D; Yaylaci, A; Hanci, D; Dogan, S; Fidan, V; Uygur, K; Keles, N; Cingi, C; Topuz, B; Çanakçioglu, S; Önerci, MObject: To prepare a national guideline for Oto-rhinolaryngologist who treat allergic rhinitis patients Methods: The study was conducted by three authors, namely the writing support team. The support team made the study plan, determined the writing instructions, chose the subgroups including the advisory committee, the advisors for authors and the authors. A workshop was organized at the very beginning to explain the details of the study to the team. Advisors took the chance to meet their coworkers in their subgroups and determined the main headings and subheadings of the guideline, together with the authors. After key words were determined by the authors, literature search was done in various databases. The authors keep in touch with the advisors and the advisors with the advisory committee and the support group at every stage of the study. National and International published articles as well as the abstracts of unpublished studies, imperatively presented in National Congresses, were included in this guideline. Only Guideline and meta-analyses published in last seven years (2013- 2017) and randomized controlled studies published in last two years (2015- 2017) were included. After all work was completed by the subgroups, support team brought all work together and edited the article. Results: A detailed guideline about all aspects of allergic rhinitis was created. Conclusion: The authors believe that this guideline will enable a compact and up-to-date information on allergic rhinitis to healthcare professionals. This guideline is the first in the field of Otolaryngology in Turkey. It should be updated at regular intervals.